Information détaillée concernant le cours
Titre | Biotechnology development (+CILS) |
Dates | 24.04.2017, 8:30-12:00; 25.04.2017: 08:30-11:15; 27.04.2017: 13:15-15:00; 02.05.2017: 08:30-12:00 et 13:30-15:00; 04.05.2017: 13:30-15:15; 08.05.2017: 11:00-12:00 et 13:30-15:15 |
Organisateur(s)/trice(s) | Prof Y. Kalia, professeur associé, Section des sciences pharmaceutiques, Université de Genève |
Intervenant-e-s | Dr Marie KOSCO-VILLEBOIS (CSO, NovImmune ) Dr Amanda PROUDFOOT Dr Zoe JOHNSON Dr Nicolas FISCHER Giovanni MAGISTRELLI Dr Keith WILSON Alexandre CARRON Dr Vanessa BUATOIS Dr Robert NELSON Dr Susana SALGADO-PIRES Rebeca ZORILLA Dr Krzysztof MASTERNAK Dr Walter FERLIN |
Description | Course Outline: • Overview of the steps for drug development (2h, MKV) • Choosing and validating a protein as a target for pharmaceutical intervention (2h, ZJ) • Discovering a therapeutic macromolecule with an emphasis on antibodies (monoclonal, bispecific, fragments) (2h, NF) • Generating a robust toolbox and screening approaches (1h, GM) • Steps in manufacturing antibodies (1h, KW) • Manufacturing a drug for market: process validation (1h, AC) • In vitro and in vivo pharmacology studies (2h, VB) • Testing samples from clinical trials and the notion of GCP (2h, RN) • Nonclinical safety: toxicology and other safety considerations before entering humans (2h, SS-P) • Pulling it all together: Project management (1h, RZ) • Awaking the immune system to fight cancer by targeting CD47 (1h, KM) • Targeting chemokines: successes and failures (1h, AP) • Targeting rare diseases: The orphan story (2h, WF) |
Lieu |
UNIGE, CMU, room A04.3011 |
Information | |
Places | 12 |
Délai d'inscription | 12.04.2017 |